Protagenic Therapeutics Inc. has announced an update regarding its business combination with Phytanix Bio Inc. The company recently generated $3.1 million in cash through warrant exchanges and exercises, which will support its operational needs and progress its peptide-based drug candidates targeting stress-related and central-nervous-system disorders. This merger brings together a total of six complementary drug programs, covering areas such as stress disorders, epilepsy, and obesity, under one entity. The collaboration aims to enhance the development of innovative treatments using both peptides and cannabinoid-like molecules.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。